Company: CNTB
Filing Date: 2025-07-22
Form Type: 8-K
Source: 0001835268-25-000047
Chunk: 1

Company: Connect Biopharma Holdings Ltd
Filing Date: 2025-07-22
Form: 8-K
Item: Item 5.02
Chunk 1
---
 Board in accordance with the Company’s standard Non-Employee Director Compensation Program, including grants to be made under the Company’s 2021 Stock Incentive Plan (the “ Plan”).

A description of the Plan and compensation practices for non-employee directors can be found in the Company’s Annual Report on Form 10-K for the year ended December 31, 2024, filed with the U. S. Securities and Exchange Commission (the “ Commission”) on March 31, 2025 (“ Form 10-K”), and in the Company’s subsequent annual and periodic reports filed with the Commission. The Plan is also filed as Exhibit 10.3 to the Form 10-K.

In connection with his appointment, Mr. Schoeneck entered into a standard indemnification agreement with the Company, in substantially the form filed as Exhibit 10.1 to the Form 10-K.

There is no arrangement or understanding between Mr. Schoeneck and any other persons pursuant to which Mr. Schoeneck was selected as a director, and there are no related party transactions involving Mr. Schoeneck that are reportable under Item 404(a) of Regulation S-K. The Board has determined that Mr. Schoeneck is an independent director in accordance with the listing requirements of The Nasdaq Stock Market LLC.

Item 9.01 Financial Statements and Exhibits.